Form 4: Recursion Pharmaceuticals CEO Exercises Stock Options

Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 28, 2024.

Summary

• On August 28, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at a price of $2.48 per share.
• Following this transaction, Gibson directly owns 752,656 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• He also holds various stock options with different exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The CEO's decision to exercise stock options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies. It provides transparency into the actions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with regulatory requirements for reporting changes in beneficial ownership.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from the CEO.

Key Dates